Back to homepage
Our offer: Antimicrobials
Experts in the fight against infectious diseases and epidemiological monitoring
Aware of the major issue represented by antibiotic and antifungal resistance, as well as the essential need to develop new antimicrobial strategies, Smaltis and its founders have been combating this scourge for over 15 years. Through its R&D work and innovative tools, Smaltis is committed to sharing its expertise in the field, assisting you in the development of your anti-infective candidates, and participating in epidemiosurveillance studies in the One Health context.
Enhance the value of your products by entrusting them to recognized experts
Whether your products are derived from chemistry, nature, microorganisms, bacteriophages, accelerate and ensure their development by entrusting them to our laboratories:
- Antibiotics
- Antifungals
- Antimicrobial peptides
- Strains with antimicrobial properties
- Bacteriophages
- Vaccines
- Antibodies
- Hygiene and disinfection products
- Any other compound with antimicrobial purposes
A comprehensive and precise offering to support your anti-infective programs
From research phases to epidemiosurveillance studies
| DEVELOPMENT STAGES |
1
RESEARCH AND SELECTION |
2
RESISTANCE RISK |
3
EPIDEMIOSURVEILLANCE |
| YOUR NEEDS |
Screening and selection of the most promising candidates, |
Anticipation of resistance that will emerge in clinical isolates, |
Monitoring the evolution of the proportion of microorganisms resistant to a molecule and the associated resistance mechanisms |
| OUR SOLUTIONS |
Determination of antimicrobial efficacy and spectrum of action, |
Study of resistance evolution through successive passages, |
Centralization and identification of strains, |
Our promise: expertise and know-how to validate and secure your developments
The development of antimicrobial products requires expertise and rigor, skills recognized at Smaltis. Our researchers accompany you with tried and tested solutions, unique tools, and informed scientific advice to overcome challenges in finding alternatives to existing antimicrobial solutions. From research stages to epidemiosurveillance studies, we work hand in hand with your teams to obtain reliable data and address the constant evolution of microorganisms.
The founders and researchers at Smaltis completed their PhDs in the field of antibiotic resistance, particularly in understanding resistance mechanisms employed by the bacterial species Pseudomonas aeruginosa. In this context, they have conducted numerous research projects contributing to the advancement of knowledge related to the fight against infections and antibiotic resistance.
The researchers at the Smaltis team are among the authors of over 50 scientific articles published in international journals related to the development of antimicrobials and the study of resistance mechanisms.
Since the beginning, Smaltis has been building specific proprietary mutant banks in various species such as Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae, presenting different and characterized antibiotic resistance profiles in perfectly controlled genetic backgrounds. These strain banks facilitate the understanding of known resistance mechanisms and help anticipate the adaptation of microorganisms to future antimicrobial molecules.
Smaltis and the Technological Research Institute Bioaster have joined forces in an exclusive collaboration to offer a unique tool to facilitate the development of new antibiotic molecules by predicting their antibacterial mechanism of action. An offering is currently in development… stay tuned!
For over 15 years, members and founders of Smaltis have surrounded themselves with experts in the field of combating antibiotic resistance, benefiting from strong scientific support, such as the National Reference Center for Antibiotic Resistance led by Professor Katy JEANNOT and the Biological Resources Center of the Jean Minjoz University Hospital in Besançon. To maintain its expertise, Smaltis regularly attends specialized conferences in the field to stay informed about advances and key issues.
Agustina LLANOS
Head of Biology
ANTABIO
We have collaborated with Smaltis on several occasions since 2014, notably as part of our ANT3273 project. This is an inhaled medicine targeting a key virulence factor of Pseudomonas aeruginosa involved in pathogenesis and would be an alternative or complement to existing antibiotic therapy for the treatment of P. aeruginosa infections in chronic respiratory diseases, such as bronchiectasis. Recently, Smaltis successfully completed a MLST sequencing project of a large number of strains with a very tight timeline to study the clonality of clinical isolates of P. aeruginosa from cystic fibrosis patients. The Smaltis team stands out for its expertise, proactive approach, and its communication and adaptability, which is why we continue to trust them.
Clara LEANDRO
Head of Infection
TECHNOPHAGE
The advancement of Technophage's therapeutic pipeline products has received crucial support from SMALTIS in the scope of genetic modification of bacterial strains. Throughout this collaborative effort, the SMALTIS scientific team has demonstrated remarkable commitment to resolving various technical challenges, successfully aligning with our objective of acquiring a set of strains for our internal utilization, all within the stipulated timeline.
Maxime GUALTIERI
CSO
NOSOPHARM
As part of our anti-infective molecule developments, we have repeatedly sought the expertise of the Smaltis team for cloning and construction of specific mutants. The services provided by Smaltis have notably contributed to our study describing and characterizing new mechanisms of resistance to Odilorhabdines in Klebsiella pneumoniae, which was published in 2021. We know that we can rely on their know-how and expert scientific advice for our future developments.
Olivier DHELLIN
Director of Pharmaceutical Development
NEOVACS
During our program to develop and industrialize the production of our Kinoïdes® vaccines, SMALTIS has proven to be a partner of choice for optimizing one of our cytokine production systems. Its service consisted in optimizing the genetic heritage of the host bacterium by excising DNA from exogenous sequences. Very attentive and with a rare expertise in microbiology, the SMALTIS team has always been benevolent and has never hesitated to guide us by providing sound advice. It is with pleasure that we will again call upon the services of SMALTIS to help us in our next challenges.
Delphine GALLAND
Head of Preclinical Clinical Studies
VETOQUINOL
For the past 10 years, we have regularly turned to Smaltis for their services and expertise in microbiology, cellular biology, and molecular biology. The entrusted work focused on evaluating the efficacy and safety of various products related to infectious diseases. The smoothness of our interactions, the responsiveness of the entire team, and their adaptation to our regulatory requirements have allowed us to advance our research projects optimally. The trust we have placed in Smaltis over these 10 years has led us to include this provider among our preferred contacts.
Eric SAMARUT
Co-founder and Scientific Director
OSTA THERAPEUTICS
Smaltis is an important partner for us, with whom we have established a close and early relationship to support the development of our new anti-infective molecules. We sought their recognized expertise in the field of antimicrobials and antibiotic resistance to support our proof of concept of the efficacy of our compounds, using specific strains from their mutant collection. With the help of growth kinetics, determination of Minimal Inhibitory Concentrations, and precise construction of mutant strains, along with their insightful advice and regular constructive exchanges, we obtained solid and essential elements to secure our data and continue our project.